The Biosimilar Revolution

Overview

Executive Summary

The European biosimilar market reached approximately $16 billion in 2025 and is projected to exceed $50 billion by 2032, growing at roughly 17-20% annually as patent cliffs accelerate across blockbuster biologics.
Between 2025 and 2030, $300 billion in branded pharmaceutical revenue faces loss of exclusivity globally, three times larger than the previous patent cliff cycle, and disproportionately concentrated in biologics.
Sandoz leads the global biosimilar market with 17% share and $3.3 billion in 2025 biosimilar revenue, followed by Pfizer (13.9%) and Amgen (12.3%). Europe remains the most mature market, contributing 38% of global biosimilar sales.
The EMA's established regulatory framework, interchangeability rulings, and national substitution policies give European manufacturers a structural advantage. Italy leads European adoption at 21% market share, followed by Germany (18%) and France (14%).
The investment case centres on three converging forces: patent cliffs creating supply-side opportunities, healthcare budget pressure creating demand-side pull, and European regulatory maturity creating a durable competitive moat.

Scale

The Magnitude of What Is at Stake

$300B

Revenue at risk by 2030

3x larger than previous cliff cycle

~70

High-revenue products facing LOE

Between 2025 and 2030

$16B

European biosimilar market (2025)

Projected to exceed $50B by 2032

The pharmaceutical industry confronts a loss-of-exclusivity wave unlike anything it has experienced. Unlike the patent cliffs of the early 2010s, which primarily affected primary care small molecules like Lipitor, this cycle targets complex biologics and specialised therapies. The products at the centre of this wave, including Keytruda, Stelara, Opdivo, and Eliquis, are not niche drugs. They are the financial engines of the world's largest pharmaceutical companies.

Exposure

Blockbusters Facing the Cliff

Drug	Company	Peak Revenue	LOE Window	Category
Keytruda	Merck	$29.5B (2023)	2028	Oncology (PD-1)
Eliquis	BMS/Pfizer	$18B+ combined	2026-2028	Cardiovascular
Stelara	J&J	$10.8B (2023)	2024-2025	Immunology
Opdivo	BMS	$9.0B	2028	Oncology (PD-1)
Humira	AbbVie	$21.2B (2022)	2023 (US)	Immunology
Eylea	Regeneron	$9.4B	2025-2027	Ophthalmology
Darzalex	J&J	$18B (2024)	Late 2020s	Oncology

Merck's Keytruda represents the single largest cliff event on the horizon, with core US exclusivity expiring around 2028. The company is already pursuing a subcutaneous reformulation to extend market share. J&J's Stelara entered its biosimilar era in 2024-2025, with sales dropping 41% in early 2025, though the company offset losses through pipeline acceleration with Tremfya and Carvykti.

Regulation

The EMA Advantage

Europe's biosimilar leadership is not accidental. It is the product of two decades of deliberate regulatory architecture. The European Medicines Agency approved the world's first biosimilar (Sandoz's Omnitrope) in 2006, nearly a decade before the US established a comparable pathway. This head start created a compounding advantage in physician familiarity, payer integration, and manufacturing capability.

Regulatory Maturity

EMA biosimilar framework operational since 2005, the earliest and most developed globally
EMA and HMA joint statement established all EU-approved biosimilars as interchangeable with reference products
National substitution policies in Germany, France, and Scandinavia accelerate uptake through tender systems

Market Dynamics

Europe accounts for 38% of global biosimilar sales, the largest regional share worldwide
Hospital penetration rates exceed 80-90% for established molecules like infliximab in markets such as Denmark and the UK
Healthcare budget pressure across the EU creates persistent demand-side pull for cost-effective biologics

Geography

European Market by Country

Source: IQVIA, IMARC Group, 2025 data.

Italy's market leadership reflects strong manufacturing capabilities and early institutional adoption of biosimilars across major therapeutic areas. Germany's position is supported by over 135 active biopharmaceutical companies and progressive substitution frameworks. France and the UK round out the top four, with the UK's NHS having achieved over 90% biosimilar penetration for infliximab.

Players

Market Leaders in Biosimilars

Company	2024 Global Share	Biosimilar Revenue	Pipeline	Key Strength
Sandoz	17.0%	$3.3B (2025)	27 assets	Vertical integration, European manufacturing
Pfizer	13.9%	$4.0B (2024)	8 marketed	Oncology portfolio, global reach
Amgen	12.3%	$3.7B (2024)	6 molecules	Biologics expertise, US market
Celltrion	~8%	~$2.5B	15+ assets	Korean manufacturing, autoimmune focus
Samsung Bioepis	~6%	~$2B	10+ assets	Partnerships with Organon, Biogen

Case Study

Sandoz: The Biosimilar Pure-Play

Since its October 2023 spin-off from Novartis, Sandoz has established itself as the definitive pure-play in affordable medicines. The company exceeded $11 billion in annual sales for the first time in 2025, with biosimilars growing 15% year-over-year to represent 30% of total revenue. Europe contributed 54% of total net sales, reinforcing the geographic concentration of value in the biosimilar market.

$11.1B

Total Sandoz revenue (2025)

Up 7% YoY reported

$3.3B

Biosimilar revenue (2025)

Up 15% YoY, 17 straight quarters of growth

21.7%

Core EBITDA margin

Up from 20.1% in 2024

Sandoz is investing over $1 billion to expand its European biosimilar manufacturing network, anchored by a new end-to-end hub in Slovenia covering technical development (Ljubljana), drug substance production (Lendava), and aseptic fill-finish (Brnik). The company's pipeline of 27 biosimilar assets targets approximately $400 billion in originator sales facing loss of exclusivity through 2034.

Thesis

Why Biosimilars Now

Supply-Side Catalyst

$300B in patent cliffs create a once-in-a-generation pipeline of biosimilar opportunities across oncology, immunology, and cardiovascular medicine.

→

Demand-Side Pull

European healthcare systems face unsustainable cost pressure. Biosimilars deliver 20-40% savings versus originator biologics, making adoption a fiscal imperative.

→

Regulatory Moat

Two decades of EMA framework maturity, physician familiarity, and established tender systems give European manufacturers a durable competitive advantage.

Assessment

Winners and Losers

Winners

Sandoz: Best-positioned pure-play with vertical integration, market-leading pipeline, and expanding European manufacturing base.
European healthcare systems: 20-40% cost savings on biologics, freeing budget for innovation and expanded patient access.
Korean manufacturers (Celltrion, Samsung Bioepis): Cost-competitive CDMO capabilities with growing direct-to-market ambitions.
Patients: Broader access to biological treatments that were previously prohibitively expensive, particularly in oncology and autoimmune disease.

Under Pressure

Bristol-Myers Squibb: Simultaneous Eliquis (2026) and Opdivo (2028) cliffs create the largest growth gap among major pharma, estimated at $38B.
Merck: Keytruda represents over half of company revenue. Subcutaneous reformulation may slow but cannot prevent erosion.
Late-entrant biosimilar developers: Crowded therapeutic categories (adalimumab now has 10+ biosimilars) compress margins for followers.
US healthcare intermediaries: Complex PBM rebate structures and slower interchangeability adoption limit US biosimilar savings versus Europe.

Monitoring

What to Watch

Keytruda Biosimilar Timeline

Multiple manufacturers are pursuing biosimilar applications for pembrolizumab. The 12-year BPCIA exclusivity expires September 2026. FDA and EMA approval timelines will determine the pace of the largest single LOE event in pharma history.

EU Pharmaceutical Strategy

The EU's evolving pharmaceutical legislation aims to further incentivise biosimilar production and adoption. Watch for changes to data exclusivity periods, mandatory substitution directives, and cross-border procurement frameworks.

GLP-1 Biosimilar Wave

Semaglutide (Ozempic/Wegovy) patents face challenges in the late 2020s. A biosimilar pathway for GLP-1 agonists would open the largest new therapeutic category for biosimilar competition since monoclonal antibodies.

Conclusion

Strategic Takeaways

The biosimilar market represents one of the clearest secular growth stories in European healthcare, underpinned by regulatory maturity, patent cliff catalysts, and structural cost pressure.
Europe's two-decade head start in biosimilar regulation creates a competitive moat that is widening, not narrowing, as complexity increases with oncology and ophthalmology biosimilars.
Sandoz is the bellwether. Its trajectory from Novartis spin-off to $11 billion independent company, with stock up 63% in its first full year, validates the pure-play biosimilar thesis.
The transition from biologics to biosimilars is slower than the equivalent small-molecule generic transition, meaning revenues erode over 3-5 years rather than overnight, creating a more predictable and investable growth curve.
Investors should watch the Keytruda biosimilar timeline closely. When pembrolizumab biosimilars reach market (likely 2028-2030), they will represent the single largest revenue transfer event in pharmaceutical history.